I like it, but not too much: Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with nmHSPC

[Maxone73]

"No patients met the primary endpoint of complete PSA response; however, 4/19 (21%) patients had a PSA decline >50%. Median PSA doubling times were 5.9 months pretreatment, 25.6 months on-treatment (p=0.001), and 9.0 months in the subsequent year off-treatment. The overall median radiographic progression-free survival was not reached. "

jitc.bmj.com/content/11/12/...

[j-o-h-n]

Shoot..... I keep hearing my echo in here........ Yodeling would be perfect right now.......If I only knew how.......

Note: I wish to offer my apologies if I offended anyone regarding my so-called humor about "race" or "misogyny". To me, humor is boundless and since we entered this word crying, I thought it would be a good idea to exit laughing.

Good Luck, Good Health and Good Humor.

j-o-h-n Sunday 12/17/2023 7:31 PM EST